Press Releases Anteris Technologies Ltd

Equities

AVR

AU0000088841

Market Closed - Australian S.E. Other stock markets 11:40:14 09/05/2024 am IST			5-day change	1st Jan Change
21.07 ^AUD	-0.14%		-1.08%	+10.03%

18/04	Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	MT
10/04	Anteris Technologies Raises AU$23 Million for DurAVR Study	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anteris talks market superiority of its biomimetic TAVR valve	01/23/01	AQ
Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023	13/23/13	BU
Anteris Technologies Ltd - DurAVR Demonstrates Exceptional Results in Second Valve-in-Valve Case	15/23/15	AQ
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	14/23/14	BU
Anteris Technologies Ltd - Montefiore Health System Enrolls Patients in the US Early Feasibility Study	10/23/10	AQ
Anteris Technologies Commences American Depository Receipt Program	09/23/09	BU
Anteris Technologies Commences US Early Feasibility Study	09/23/09	BU
Anteris welcomes successful DurAVR valve-in-valve procedure	01/23/01	AQ
Anteris Technologies Ltd - First Successful Implantation of DurAVR THV in a Valve-in-Valve Procedure	01/23/01	AQ
Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure	31/23/31	BU
Anteris Technologies says latest first-in-human DurAVRÃ¢„¢ results are next-level	15/23/15	AQ
Anteris says new repair device provides another shot on goal for multi-billion dollar product	27/23/27	AQ
Anteris Technologies CEO talks A$35 million raise and 2023 milestones	16/23/16	AQ
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts	15/23/15	BU
Anteris Technologies hails FDA early feasibility study approval for DurAVRÃ¢„¢	06/22/06	AQ
Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR™	28/22/28	BU
Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston	13/22/13	BU
Anteris Technologies : Application for quotation of securities - AVR	05/22/05	PU
Anteris Technologies : Application for quotation of securities - AVR	17/22/17	PU
Anteris Technologies : Application for quotation of securities - AVR	10/22/10	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Anteris Technologies Ltd

Equities

AVR

AU0000088841

Press Releases

Filters